Wolfgang Miesbach/LinkedIn
May 13, 2026, 15:10
Wolfgang Miesbach: Rethinking Bleeding Risk in Anticoagulation
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Rethinking Bleeding Risk in Anticoagulation.
At the EHA‑SWG Scientific Meeting on Bleeding and Platelet Disorders, Mariantonietta Tripodo delivered a fantastic talk on bleeding risk in patients receiving antithrombotic therapy – from AF and VTE to prosthetic valves, LV thrombus and acute coronary syndromes:
- Antithrombotic therapy is used across many indications, so managing bleeding risk is a daily challenge in routine practice.
- Major bleeding (incl. ICH) remains a major limitation of VKAs and DOACs, and ‘fear‑driven’ underdosing in real life is still common.
- High‑risk patients (age, renal impairment, prior bleeding) live within a narrow therapeutic window, making individualized decisions essential.
- Targeting FXI could help decouple thrombosis from hemostasis, with early data suggesting relevant bleeding reduction while preserving efficacy.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
May 13, 2026, 15:09Veronica Sanchez: Better Cardiovascular Health Helps Lower Heart Attack Risk
-
May 13, 2026, 15:07Tung Nguyen Thanh: New Perspective on Thrombosis in Hematological Malignancies in Vietnam
-
May 13, 2026, 15:03Haji Siyamuddin Ansari: The Key Difference Between Plasma and Serum
-
May 13, 2026, 14:45Masoabi Sefojane: The Cost of a 35-Year Diagnosis Delay
-
May 13, 2026, 14:39Ahmed Mohsen: Managing DVT During Pregnancy and Lactation
-
May 13, 2026, 14:38The Coffee Shop Origins of Factor V Leiden – ISTH
-
May 13, 2026, 14:33Moustafa Abdou: Could a Commonly Prescribed Drug Trigger Life-Threatening Hemolysis?
-
May 13, 2026, 14:04Lester Leung: The Lancet Highlights TAPIS Trial at ESOC 2026
-
May 13, 2026, 13:15Priyanka Kasatkar: How One Research Idea Became a Diagnostic Innovation in Hemostasis